Individuals with kidney disease retain the ability to generate EPO, and desidustat, categorized as an oral HIF-PHI, triggers the production of endogenous EPO, maintaining levels within or close to the physiological range and resulting in an elevation of Hb levels. The gene discussed is EPO; the disease is kidney disorder.